IP Library › Granted Patent US 12,351,645
Granted Patent B2
US 12,351,645 · App. 17/051,635 · Granted Jul 8, 2025

Anti-carbonic anhydrase IX antibody

Inventors: Bor-Yu Tsai (New Taipei, TW); Wei-Ting Hsu (Taipei, TW)
Assignee: NAVI BIO-THERAPEUTICIS, INC.
C07K16/30C07K16/40C07K2317/34C07K2317/622C07K2317/92C12Y402/01001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,645
App. No.
17/051,635
Granted
Jul 8, 2025
Kind
B2
Abstract

The present invention relates to epitopes located in CAIX and anti-CAIX antibodies having binding activity with cancer cells. The present invention also relates to the composition and application of the CAIX epitopes and anti-CAIX antibodies in the diagnosis, prevention and/or treatment of cancers.

Claims (23)

1. An isolated anti-carbonic anhydrase IX (CAIX) antibody or antigen-binding portion thereof, comprising:

a light chain complementarity determining region 1 (L-CDR1) of SEQ ID NO:4; a light chain CDR2 (L-CDR2) of SEQ ID NO:5; and a light chain CDR3 (L-CDR3) of SEQ ID NO:3; and

a heavy chain CDR1 (H-CDR1) of SEQ ID NO:12; a heavy chain CDR2 (H-CDR2) of SEQ ID NO:13; and a heavy chain CDR3 (H-CDR3) of SEQ ID NO:14; such that said isolated antibody or antigen-binding portion thereof binds to CAIX.

2. The isolated anti-CAIX antibody or antigen-binding portion thereof of claim 1 , wherein the antibody is a monoclonal antibody, chimeric antibody, or humanized antibody.

3. The isolated anti-CAIX antibody or antigen-binding portion thereof of claim 1 , which comprises a constant region and one or more heavy and light chain variable framework regions of a human antibody sequence.

4. The isolated anti-CAIX antibody or antigen-binding portion thereof of claim 3 , which comprises up to 10 amino acid substitutions in the framework regions.

5. The isolated anti-CAIX antibody or antigen-binding portion thereof of claim 3 , which comprises framework regions of Avastin.

6. The isolated anti-CAIX antibody or antigen-binding portion thereof of claim 3 , wherein the framework regions comprise L-FR1 having an amino acid sequence of SEQ ID NO: 34, L-FR2 having an amino acid sequence of SEQ ID No: 38, L-FR3 having an amino acid sequence of SEQ ID NO: 41 and L-FR4 having an amino acid sequence of SEQ ID NO: 44 and H-FR1 having an amino acid sequence of SEQ ID NO: 47, H-FR2 having an amino acid sequence of SEQ ID NO: 54, H-FR3 having an amino acid sequence of SEQ ID NO: 58 and H-FR4 having an amino acid sequence of SEQ ID NO:64.

7. The isolated anti-CAIX antibody or antigen-binding portion thereof of claim 1 , wherein the light chain comprises an amino acid sequence having a sequence as set forth in SEQ ID NO: 22.

8. The isolated anti-CAIX antibody or antigen-binding portion thereof of claim 1 , wherein the heavy chain comprises an amino acid sequence having a sequence as set forth in SEQ ID NO: 25; or an antigen-binding portion thereof.

9. The isolated anti-CAIX antibody or antigen-binding portion thereof of claim 1 , which comprises a light chain having an amino acid sequence as set forth in SEQ ID NO: 22 and a heavy chain having an amino acid sequence as set forth in SEQ ID NO: 25.

10. The isolated anti-CAIX antibody or antigen-binding portion thereof of claim 1 , wherein the antigen-binding portion is Fab, F(ab′)2, Fd, Fv, dAb or scFv.

11. A pharmaceutical composition comprising the isolated anti-CAIX antibody or antigen-binding portion thereof of claim 1 and a pharmaceutically acceptable carrier or excipient.

12. The pharmaceutical composition of claim 11 , which further comprises one or more additional anti-cancer drug.

13. A method for treating cancer in a subject comprising administering the isolated anti-CAIX antibody or antigen-binding portion thereof of claim 4 to the subject.

14. The method of claim 13 , which further comprises a step of administering one or more additional anti-cancer drugs concurrently, subsequently, or separately with the isolated anti-CAIX antibody or antigen-binding portion thereof of claim 1 .

15. A single chain variable fragment (scFv) that binds CAIX, comprising:

a) a light chain variable region of a light chain having an amino acid sequence as set forth in the sequence of SEQ ID NO: 22;

b) a linker; and

c) a heavy chain variable region of a heavy chain having an amino acid sequence as set forth in the sequence of SEQ ID NO: 25.

16. The scFv of claim 15 , wherein the linker is a peptide linker.

17. The scFv of claim 15 , wherein the linker comprises 4-20 amino acids.

18. The scFv of claim 15 , wherein the linker comprises a peptide having an amino acid sequence of SEQ ID NO:29, 30 or 31.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2021
From: NAVI BIO-THERAPEUTICS, LLC
To: NAVI BIO-THERAPEUTICS, INC.
Reel/Frame 057286/0043 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2020
From: TSAI, BOR-YU; HSU, WEI-TING; HUANG, YU HSUAN
To: NAVI BIO-THERAPEUTICS, LLC
Reel/Frame 054616/0121 →
Continuity (1)
Related Publication 20220049012A1 · Feb 17, 2022
References Cited (34)
US 20040018198A1 · Gudas et al. · 2004 [cited by applicant]
US 20050031623A1 · Pastorek et al. · 2005 [cited by applicant]
US 20090068095A1 · Marasco et al. · 2009 [cited by applicant]
US 20130022640A1 · Hurwitz et al. · 2013 [cited by applicant]
US 20160289337A1 · Abrahmsén et al. · 2016 [cited by applicant]
US 20180030147A1 · Marasco et al. · 2018 [cited by applicant]
US 20180072813A1 · Marasco et al. · 2018 [cited by applicant]
US 20180186893A1 · Lenferink et al. · 2018 [cited by applicant]
CN 108064251A · 2018 [cited by applicant]
JP 2005535601A · 2005 [cited by applicant]
WO 03100029A2 · 2003 [cited by applicant]
WO 2003100029A2 · 2003 [cited by applicant]
WO 2004017923A2 · 2004 [cited by applicant]
WO 2011139375A1 · 2011 [cited by applicant]
WO 2012072788A1 · 2012 [cited by applicant]
WO 2016100980A1 · 2016 [cited by applicant]
WO 2016199097A1 · 2016 [cited by applicant]
WO 2017048850A1 · 2017 [cited by applicant]
WO 2017189964A2 · 2017 [cited by applicant]
Rudikoff et al., (PNAS 79: 1979-1983, 1982) (Year: 1982). [cited by examiner]
Paul, Fundamental Immunology, (textbook), 292-295, 1993 (Year: 1993). [cited by examiner]
Colman P. M. (Research in Immunology, 145:33-36, 1994) (Year: 1994). [cited by examiner]
Brummell et al. (Biochemistry 32:1180-1187 1993) (Year: 1993). [cited by examiner]
A549, A549 cell—Wikipedia downloaded on Aug. 18, 2024, pp. 1-3 (Year: 2024). [cited by examiner]
Office Action with Search Report issued in Chinese patent application No. 2019800961438 on Jan. 10, 2024. [cited by applicant]
Ahlskog, JKJ et al., “Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours”, British Journal of Cancer, vol. 101, No. 4, Jul. 21, 2009 (Jul. 21, 2009)… [cited by applicant]
Araste, Fatemeh et al., “A novel VHH nanobody against the active site (the CA domain) of tumor-associated, carbonic anhydrase isoform IX and its usefulness for cancer diagnosis”, Biotechnology Letters, vol. 36, No. 1, S… [cited by applicant]
Mboge, Mam Y. et al. “Advances in Anti-Cancer Drug Development Targeting Carbonic Anhydrase IX and XII” In: “Topics in Anti-Cancer Research”, Dec. 18, 2016 (Dec. 18, 2016), Bentham Science Publishers, XP055596596, ISBN:… [cited by applicant]
Murri-Plesko, Margarita T. et al. “Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX”, European Journal of Pharmacology, Elsevier Science, NL, vol. 657, No. 1, Jan. 27, 2011 (Jan.… [cited by applicant]
Office Action issued in European Patent Application No. 19928127.0 on Oct. 18, 2022. [cited by applicant]
Office Action issued in Japan Patent Application No. 2021-566230 on Mar. 7, 2023. English Machine Translation Included. [cited by applicant]
Xu, Chen et al, “Unique Biological Properties of Catalytic Domain Directed Human Anti-CAIX Antibodies Discovered through Phage-Display Technology”, PLOS ONE, vol. 5, No. 3, Mar. 10, 2010 (Mar. 10, 2010), p. e9625, XP055… [cited by applicant]
Zatovicova, M. et al., “Carbonic Anhydrase IX as an Anticancer Therapy Target: Preclinical Evaluation of Internalizing Monoclonal Antibody Directed to Catalytic Domain”, Current Pharmaceutical Design, vol. 16, No. 29, O… [cited by applicant]
Zatovicova, Miriam et al, “Monoclonal antibody G250 targeting CA IX: Binding specificity, internalization and therapeutic effects in a non-renal cancer model”, International Journal of Oncology, vol. 45, No. 6, Sep. 17,… [cited by applicant]